Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in 

-positive non—small cell lung cancer (NSCLC).

Crizotinib (Xalkori), the current standard of care, does not have good central nervous system (CNS) penetration; therefore, CNS metastases cannot be well controlled. However, entrectinib is a very CNS-penetrant brain metastases-active compound, says Doebele.

Entrectinib may allow for better upfront control of existing brain metastases, and may prevent the development of brain metastases in the future.

Videos

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non-small cell lung cancer.

Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLC

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with 

The findings of the phase II clinical trial of entrectinib in 

-positive NSCLC achieved an objective response rate (ORR) of 78% and a median progression-free survival (PFS) of approximately 30 months, Doebele explains.

The significance of these results, Doebele adds, is that entrectinib could potentially be a central nervous system (CNS)-active tyrosine kinase inhibitor for 

-positive NSCLC. In this trial, there were 6 patients evaluated with CNS metastases, 5 of whom had a response and demonstrated an ORR of 83%. This is likely driving a longer PFS in these patients. In conclusion, this could potentially be a frontline option for patients with this molecular abnormality.

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non

Robert C. Doebele, MD, PhD

Articles

Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLC

Dr. Doebele on Significant Findings of Entrectinib in Patients With ROS1+ NSCLC